Time and information are the most powerful tools in the fight against cancer. Sema4 Signal WES/WTS maximizes both.

 

You shouldn’t have to run multiple sequential panels to unlock the answers to your patient’s cancer. Sema4 Signal WES/WTS integrates tumor-normal matched whole exome sequencing (WES) with whole transcriptome sequencing (WTS) in one comprehensive test to rapidly deliver the most in-depth molecular insights, and enable clinical care, research, and trial discovery.

 

Compared with running multiple sequential panels, Sema4 Signal WES/WTS provides:

More information, faster TAT, smaller sample size, lower cost,

reduced administrative burden, and a single comprehensive report

WES (DNA)

  • Delivers data from ~18,500 genes to provide the most in-depth profile of a patient’s cancer
  • Tumor-normal matching helps distinguish somatic and germline variants
  • The gold standard method for measuring tumor mutational burden (TMB)

WTS (RNA)

    • Provides information on gene fusions and splice variants to help define molecular signatures, stratify risk, and inform the use of targeted therapies

 

WES + WTS

By pairing WES with WTS, Sema4 provides information that meets the current and future needs of cancer patients, enabling their providers to identify therapies and clinical trials today and take advantage of those of tomorrow. We employ tumor-normal matching to provide information on germline contributions, which can inform treatment in a significant proportion of advanced cancer patients. Read more about our advanced technologies.

Sema4 Signal WES/WTS and PanCancer and can detect >99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials

 

Is 18,500 genes more information than you need?

Consider Sema4 Signal PanCancer:

Panel analysis of 2,200 genes, run on a comprehensive WES/WTS backbone >>

 

Sema4 Signal WES/WTS can help providers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Determine diagnoses and prognoses

    • Detects alterations including single nucleotide variants (SNVs), insertions and deletions (InDels), copy number variants (CNVs), arm-length aneuploidies, and RNA splice variants and fusions
    • Analyzes immuno-oncology biomarkers, including PD-L1, DNA mismatch repair (MMR), microsatellite instability (MSI), and TMB

 

Seamlessly access testing

    • Workflow integration (EMR, Sema4 Provider Portal)
    • Genetic counseling for all positive germline findings
    • Broad network coverage, supportive billing policies
    • Sample coordination services
    • Learn more about our somatic testing support services

 

Identify available targeted therapies

    • Clinically actionable findings are presented on the first page of the easy-to-read results report
    • Can identify variants not picked up by targeted panels, to inform decisions for patients for whom standard treatment has failed

 

Identify suitable clinical trials

    • Current trials are outlined in the comprehensive results report
    • May be tailored to prioritize trials at the provider’s institution
    • By combining somatic testing with Sema4 Signal informatics tools, providers can leverage real-world data to enable advanced trial matching

 

Discover hereditary cancer contributions

    • Germline findings may inform treatment and management, including whether a patient qualifies for PARP inhibitors
    • Further testing can be done with Sema4 Signal Hereditary Cancer

 

Learn about non-cancer germline findings

    • 59 non-cancer genes

 

WES/WTS and PanCancer Interactive Lookup Tool

Find information on specific cancer genes included in our WES/WTS and PanCancer tests

 

Resources

 

Connect with us today

Kindly fill out the form below and we’ll schedule a time to discuss your needs. Or feel free to call us at 833-486-6260.
 



 

NCCN guidelines: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Guideline Name V.X.2019. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 10, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility of their application or use in any way.